cefazolin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	530	25953-19-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefazolin cefazolin sodium cefamezin cefaprim cefazoline cephamezine cephazolin cephazoline cefazolin sodium salt	A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. Molecular weight: 454.50 Formula: C14H14N8O4S3 CLOGP: -0.64 LIPINSKI: 1 HAC: 12 HDO: 2 TPSA: 156.09 ALOGS: -2.97 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefazolin
cefazolin sodium
cefamezin
cefaprim
cefazoline
cephamezine
cephazolin
cephazoline
cefazolin sodium salt

A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Molecular weight: 454.50
Formula: C14H14N8O4S3
CLOGP: -0.64
LIPINSKI: 1
HAC: 12
HDO: 2
TPSA: 156.09
ALOGS: -2.97
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	33 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	80 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	146.75 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.89 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.18 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 4, 1973	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	604.84	13.98	226	15660	23407	63449729
Anaphylactic reaction	279.14	13.98	185	15701	65915	63407221
Hypotension	196.57	13.98	288	15598	272316	63200820
Acute generalised exanthematous pustulosis	178.45	13.98	76	15810	11023	63462113
Arthrodesis	155.65	13.98	48	15838	2753	63470383
Postoperative wound infection	115.93	13.98	56	15830	10869	63462267
Fatigue	95.60	13.98	52	15834	887976	62585160
Bronchospasm	91.84	13.98	56	15830	17224	63455912
Erythema	83.37	13.98	154	15732	175597	63297539
Type I hypersensitivity	81.99	13.98	30	15856	2912	63470224
Exposure during pregnancy	73.37	13.98	136	15750	155411	63317725
Urticaria	70.85	13.98	139	15747	165663	63307473
Cardiac arrest	66.72	13.98	98	15788	92447	63380689
Tachycardia	64.30	13.98	110	15776	118046	63355090
Vitamin K deficiency	63.78	13.98	16	15870	424	63472712
Drug hypersensitivity	63.44	13.98	196	15690	310491	63162645
Shoulder arthroplasty	59.70	13.98	26	15860	3976	63469160
Premature delivery	59.70	13.98	54	15832	30227	63442909
Premature baby	59.62	13.98	46	15840	20689	63452447
Amniotic cavity infection	59.16	13.98	19	15867	1244	63471892
Limb operation	56.28	13.98	25	15861	4006	63469130
Drug-induced liver injury	55.48	13.98	59	15827	40163	63432973
Hypoprothrombinaemia	54.48	13.98	13	15873	278	63472858
Blood pressure decreased	52.96	13.98	73	15813	64949	63408187
Renal failure	51.88	13.98	100	15786	117552	63355584
Kounis syndrome	49.54	13.98	18	15868	1712	63471424
Anaesthetic complication	47.35	13.98	18	15868	1942	63471194
Alopecia	47.29	13.98	13	15873	337523	63135613
Bradycardia	44.95	13.98	72	15814	73155	63399981
Drug intolerance	44.93	13.98	11	15875	308650	63164486
Maternal exposure during delivery	44.42	13.98	16	15870	1484	63471652
Renal injury	43.62	13.98	28	15858	9411	63463725
Rash	41.74	13.98	261	15625	560610	62912526
Coagulopathy	41.20	13.98	37	15849	20507	63452629
Recurrence of neuromuscular blockade	40.72	13.98	9	15877	135	63473001
Toxic epidermal necrolysis	40.06	13.98	40	15846	25294	63447842
Acute hepatic failure	38.73	13.98	34	15852	18293	63454843
Vascular purpura	37.25	13.98	14	15872	1464	63471672
Fear	36.88	13.98	31	15855	15735	63457401
Multiple organ dysfunction syndrome	36.48	13.98	57	15829	56695	63416441
Systemic lupus erythematosus	35.61	13.98	5	15881	208913	63264223
Anhedonia	35.21	13.98	26	15860	10948	63462188
Product dose omission issue	34.78	13.98	8	15878	234305	63238831
Headache	34.04	13.98	67	15819	633174	62839962
Generalised tonic-clonic seizure	33.86	13.98	39	15847	28977	63444159
Pseudomembranous colitis	33.15	13.98	16	15870	3096	63470040
Weight increased	33.02	13.98	12	15874	260780	63212356
Purpura senile	32.77	13.98	10	15876	553	63472583
Post procedural complication	32.77	13.98	30	15856	17044	63456092
Tarsal tunnel syndrome	32.58	13.98	10	15876	564	63472572
Peripheral swelling	32.41	13.98	13	15873	265929	63207207
Unevaluable event	32.18	13.98	51	15835	51335	63421801
Isoimmune haemolytic disease	31.95	13.98	6	15880	37	63473099
Disseminated intravascular coagulation	31.83	13.98	31	15855	19020	63454116
Hepatic function abnormal	30.68	13.98	42	15844	37100	63436036
Face oedema	30.29	13.98	31	15855	20181	63452955
Cholestasis	30.12	13.98	37	15849	29397	63443739
Wound	30.06	13.98	3	15883	163260	63309876
Clostridium test positive	29.76	13.98	15	15871	3186	63469950
Swelling	29.63	13.98	16	15870	275362	63197774
Sinusitis	29.43	13.98	10	15876	226643	63246493
Thrombotic microangiopathy	29.42	13.98	23	15863	10538	63462598
Oxygen saturation decreased	29.34	13.98	67	15819	88518	63384618
Angioedema	29.20	13.98	47	15839	47918	63425218
Joint swelling	28.61	13.98	24	15862	327642	63145494
Therapeutic product effect decreased	27.87	13.98	7	15879	193180	63279956
Acute kidney injury	27.85	13.98	135	15751	263280	63209856
Foetal anaemia	26.79	13.98	6	15880	96	63473040
Pain	26.43	13.98	96	15790	740532	62732604
Hepatitis cholestatic	25.98	13.98	18	15868	6860	63466276
Pain in extremity	25.74	13.98	27	15859	331459	63141677
Toxic skin eruption	25.43	13.98	23	15863	12862	63460274
Death	25.33	13.98	34	15852	374347	63098789
Hyperthermia malignant	25.09	13.98	9	15877	825	63472311
Post procedural haematoma	24.70	13.98	10	15876	1275	63471861
Malaise	24.09	13.98	42	15844	415912	63057224
Infusion related reaction	23.97	13.98	16	15870	245505	63227631
Haemolytic anaemia	23.87	13.98	20	15866	10105	63463031
Treatment failure	23.80	13.98	10	15876	199033	63274103
Tonic clonic movements	23.63	13.98	10	15876	1425	63471711
Altered state of consciousness	23.09	13.98	30	15856	25200	63447936
Pleural effusion	22.98	13.98	63	15823	93147	63379989
Implant site haematoma	22.50	13.98	5	15881	77	63473059
Eosinophilia	22.31	13.98	28	15858	22728	63450408
Heparin-induced thrombocytopenia	22.19	13.98	14	15872	4568	63468568
Resorption bone increased	21.39	13.98	9	15877	1265	63471871
Low birth weight baby	20.89	13.98	16	15870	7113	63466023
Injury	20.59	13.98	52	15834	73195	63399941
Nasopharyngitis	20.54	13.98	20	15866	254237	63218899
Vestibular disorder	20.38	13.98	9	15877	1422	63471714
Drug reaction with eosinophilia and systemic symptoms	20.38	13.98	33	15853	33803	63439333
Aspartate aminotransferase increased	20.28	13.98	59	15827	90218	63382918
Pulseless electrical activity	20.13	13.98	16	15870	7505	63465631
Shock	20.08	13.98	27	15859	23436	63449700
Staphylococcal bacteraemia	19.79	13.98	14	15872	5516	63467620
Asthenia	19.36	13.98	42	15844	383562	63089574
Mixed liver injury	19.33	13.98	13	15873	4722	63468414
Post procedural haemorrhage	19.33	13.98	16	15870	7948	63465188
Eyelid oedema	19.31	13.98	18	15868	10461	63462675
Hypoventilation	19.28	13.98	13	15873	4741	63468395
Clostridium difficile infection	19.14	13.98	30	15856	29892	63443244
Pyomyositis	19.04	13.98	6	15880	369	63472767
Lip oedema	19.02	13.98	12	15874	3912	63469224
Arthralgia	18.89	13.98	76	15810	569634	62903502
Alanine aminotransferase increased	18.85	13.98	63	15823	103707	63369429
Hypokalaemia	18.84	13.98	63	15823	103741	63369395
Laryngeal dyspnoea	18.59	13.98	5	15881	175	63472961
Hepatic cytolysis	18.46	13.98	21	15865	15386	63457750
Spinal cord haematoma	18.46	13.98	5	15881	180	63472956
Eosinophilic pneumonia acute	18.29	13.98	6	15880	420	63472716
Shock haemorrhagic	18.24	13.98	17	15869	9878	63463258
Manipulation	18.23	13.98	4	15882	58	63473078
Cerebral infarction	18.21	13.98	26	15860	23867	63449269
Injection site pain	18.15	13.98	5	15881	129795	63343341
Musculoskeletal stiffness	18.06	13.98	12	15874	184606	63288530
Mycobacterial peritonitis	18.04	13.98	4	15882	61	63473075
Oligohydramnios	18.03	13.98	14	15872	6352	63466784
Allergy test negative	17.97	13.98	5	15881	199	63472937
Respiratory failure	17.76	13.98	61	15825	101797	63371339
Glomerular filtration rate abnormal	17.76	13.98	7	15879	832	63472304
Procedural complication	17.70	13.98	13	15873	5426	63467710
Abdominal wound dehiscence	17.49	13.98	5	15881	220	63472916
Haemodynamic instability	17.34	13.98	16	15870	9174	63463962
Emotional distress	17.28	13.98	30	15856	32519	63440617
Device related infection	17.16	13.98	25	15861	23367	63449769
Deep vein thrombosis	17.15	13.98	53	15833	83747	63389389
Linear IgA disease	17.11	13.98	8	15878	1443	63471693
Circulatory collapse	16.91	13.98	24	15862	21914	63451222
Weight decreased	16.88	13.98	27	15859	276771	63196365
Gastrointestinal disorder	16.66	13.98	6	15880	131233	63341903
Clostridium difficile colitis	16.59	13.98	23	15863	20546	63452590
Jaundice acholuric	16.44	13.98	4	15882	93	63473043
Anaemia	16.11	13.98	127	15759	293303	63179833
Intentional product use issue	15.98	13.98	6	15880	127886	63345250
Decorticate posture	15.96	13.98	5	15881	302	63472834
Dizziness	15.77	13.98	55	15831	429870	63043266
Renal impairment	15.48	13.98	53	15833	88302	63384834
Therapeutic product effect incomplete	15.40	13.98	6	15880	125050	63348086
Irregular breathing	15.34	13.98	5	15881	343	63472793
Arthrofibrosis	15.30	13.98	3	15883	24	63473112
Apnoea	15.20	13.98	14	15872	8008	63465128
Toxicity to various agents	15.19	13.98	24	15862	247226	63225910
Insomnia	15.10	13.98	19	15867	215233	63257903
Discomfort	14.91	13.98	12	15874	167362	63305774
Peritoneal cloudy effluent	14.88	13.98	4	15882	140	63472996
Brain oedema	14.77	13.98	18	15868	14177	63458959
Renal vein thrombosis	14.63	13.98	5	15881	397	63472739
Mobility decreased	14.62	13.98	6	15880	121153	63351983
Multiple lentigines syndrome	14.51	13.98	4	15882	154	63472982
Hypopnoea	14.47	13.98	10	15876	3796	63469340
Septic shock	14.44	13.98	43	15843	66586	63406550
Atelectasis	14.39	13.98	22	15864	21461	63451675
Hypoxia	14.32	13.98	40	15846	59752	63413384
Delivery	14.30	13.98	7	15879	1396	63471740
Keratitis fungal	14.29	13.98	4	15882	163	63472973
Serratia test positive	14.27	13.98	3	15883	35	63473101
Bradycardia foetal	14.24	13.98	5	15881	431	63472705
Muscle spasms	14.15	13.98	11	15875	156139	63316997
Endotracheal intubation complication	14.11	13.98	5	15881	442	63472694

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	391.99	14.89	169	13831	15772	34927159
Anaphylactic reaction	273.97	14.89	167	13833	32134	34910797
Hypoprothrombinaemia	160.79	14.89	36	13964	346	34942585
Kounis syndrome	97.35	14.89	37	13963	2481	34940450
Fear	96.01	14.89	57	13943	10419	34932512
Drug reaction with eosinophilia and systemic symptoms	82.87	14.89	83	13917	32929	34910002
Thymus hypoplasia	80.65	14.89	21	13979	397	34942534
Lymphoid tissue hypoplasia	80.65	14.89	21	13979	397	34942534
Hypotension	79.42	14.89	231	13769	221418	34721513
Renal injury	75.14	14.89	50	13950	11145	34931786
Anhedonia	74.05	14.89	43	13957	7542	34935389
Injury	73.20	14.89	63	13937	20624	34922307
Acute generalised exanthematous pustulosis	73.09	14.89	41	13959	6735	34936196
Disseminated aspergillosis	67.70	14.89	21	13979	759	34942172
Emotional distress	61.95	14.89	50	13950	14976	34927955
Clostridium difficile colitis	59.94	14.89	50	13950	15680	34927251
Fatigue	59.10	14.89	38	13962	370615	34572316
Bronchospasm	55.82	14.89	41	13959	10690	34932241
Vitamin K deficiency	54.20	14.89	14	13986	256	34942675
Allergy test negative	53.25	14.89	12	13988	119	34942812
Urticaria	53.08	14.89	92	13908	62285	34880646
Hypovitaminosis	51.43	14.89	16	13984	584	34942347
Erythema	46.62	14.89	107	13893	88673	34854258
Clostridium test positive	43.77	14.89	23	13977	3319	34939612
Unevaluable event	43.14	14.89	59	13941	32531	34910400
Brain herniation	42.54	14.89	24	13976	3984	34938947
Post procedural hypotension	42.36	14.89	9	13991	66	34942865
Death	41.14	14.89	60	13940	397989	34544942
Post procedural complication	40.92	14.89	35	13965	11353	34931578
Vitamin K decreased	39.33	14.89	8	13992	46	34942885
Dizziness	38.16	14.89	20	13980	218501	34724430
Tubulointerstitial nephritis	37.22	14.89	44	13956	20980	34921951
Cytomegalovirus viraemia	35.54	14.89	27	13973	7403	34935528
Rash maculo-papular	35.39	14.89	50	13950	28401	34914530
Blood pressure decreased	35.02	14.89	69	13931	51446	34891485
Rash	34.45	14.89	178	13822	222574	34720357
Coagulopathy	34.35	14.89	41	13959	19748	34923183
Shock	33.86	14.89	45	13955	24134	34918797
Weight decreased	32.48	14.89	15	13985	176286	34766645
Hyperthermia malignant	31.44	14.89	16	13984	2161	34940770
Adrenal suppression	30.50	14.89	11	13989	636	34942295
Post procedural haematoma	30.46	14.89	14	13986	1512	34941419
Gastritis fungal	29.77	14.89	7	13993	85	34942846
Metabolic acidosis	29.07	14.89	58	13942	43622	34899309
Jaundice cholestatic	28.80	14.89	20	13980	4774	34938157
Renal failure	28.07	14.89	115	13885	130442	34812489
Pathogen resistance	27.83	14.89	26	13974	9456	34933475
Coagulation factor X level decreased	27.45	14.89	5	13995	14	34942917
Linear IgA disease	26.58	14.89	13	13987	1613	34941318
Multiple organ dysfunction syndrome	26.51	14.89	79	13921	76487	34866444
Ventricular tachycardia	26.33	14.89	42	13958	26537	34916394
Pericarditis fungal	25.83	14.89	7	13993	155	34942776
Eosinophilia	25.38	14.89	41	13959	26181	34916750
Angioedema	25.32	14.89	50	13950	37324	34905607
Renal impairment	25.04	14.89	89	13911	94424	34848507
Serotonin syndrome	24.74	14.89	35	13965	19898	34923033
Fungal infection	24.40	14.89	31	13969	15904	34927027
Pseudomonal sepsis	24.17	14.89	16	13984	3531	34939400
Device related infection	24.01	14.89	32	13968	17205	34925726
Hepatic function abnormal	23.84	14.89	54	13946	44309	34898622
Rash morbilliform	23.68	14.89	15	13985	3072	34939859
Stress	23.52	14.89	43	13957	30304	34912627
Meningitis fungal	23.27	14.89	6	13994	109	34942822
Embolic stroke	23.12	14.89	17	13983	4437	34938494
Strongyloidiasis	22.89	14.89	14	13986	2697	34940234
Type I hypersensitivity	22.77	14.89	11	13989	1328	34941603
Toxic epidermal necrolysis	22.54	14.89	35	13965	21611	34921320
Burkholderia test positive	22.36	14.89	10	13990	1013	34941918
Product dose omission issue	22.32	14.89	10	13990	119701	34823230
Malaise	22.24	14.89	25	13975	185800	34757131
Arterial angioplasty	22.15	14.89	5	13995	50	34942881
Drug eruption	21.88	14.89	33	13967	19865	34923066
Toxicity to various agents	21.82	14.89	29	13971	200333	34742598
Diarrhoea	21.54	14.89	82	13918	389830	34553101
Myoclonus	21.53	14.89	28	13972	14697	34928234
Anaesthetic complication	21.50	14.89	10	13990	1110	34941821
Conjunctival ulcer	21.47	14.89	5	13995	58	34942873
Intrapericardial thrombosis	21.47	14.89	5	13995	58	34942873
Drug hypersensitivity	21.47	14.89	76	13924	80453	34862478
Spontaneous haematoma	21.22	14.89	8	13992	524	34942407
Headache	20.89	14.89	30	13970	200605	34742326
Cardiac arrest	20.88	14.89	85	13915	96074	34846857
Post embolisation syndrome	20.74	14.89	5	13995	68	34942863
Catheter site haemorrhage	20.10	14.89	12	13988	2212	34940719
Factor V inhibition	20.07	14.89	6	13994	191	34942740
Procedural hypotension	19.98	14.89	9	13991	927	34942004
Pyrexia	19.38	14.89	211	13789	332802	34610129
Lymphopenia	19.27	14.89	28	13972	16307	34926624
Tachycardia	19.26	14.89	76	13924	84696	34858235
Post procedural haemorrhage	19.25	14.89	20	13980	8269	34934662
Kidney transplant rejection	19.07	14.89	19	13981	7478	34935453
Tryptase increased	18.98	14.89	6	13994	231	34942700
Drug-induced liver injury	18.84	14.89	38	13962	28794	34914137
Herpes simplex hepatitis	18.80	14.89	5	13995	103	34942828
Cellulitis	18.66	14.89	55	13945	52896	34890035
Viral uveitis	18.52	14.89	4	13996	32	34942899
Disseminated intravascular coagulation	18.30	14.89	32	13968	21784	34921147
Cardiac valve vegetation	18.20	14.89	7	13993	484	34942447
Asthenia	18.20	14.89	45	13955	245206	34697725
Coagulation factor VII level decreased	18.07	14.89	5	13995	120	34942811
Dysbiosis	17.76	14.89	7	13993	517	34942414
Systemic mastocytosis	17.17	14.89	5	13995	145	34942786
Pruritus	16.97	14.89	106	13894	141875	34801056
Haemodynamic instability	16.97	14.89	20	13980	9503	34933428
Bacterial infection	16.95	14.89	27	13973	17036	34925895
Eyelid oedema	16.90	14.89	15	13985	5109	34937822
Blood creatine phosphokinase MB increased	16.59	14.89	10	13990	1876	34941055
Appendicitis perforated	16.48	14.89	10	13990	1898	34941033
Drug chemical incompatibility	16.32	14.89	3	13997	9	34942922
Arteritis	16.31	14.89	6	13994	367	34942564
Nodal rhythm	16.29	14.89	9	13991	1434	34941497
Torsade de pointes	16.03	14.89	17	13983	7192	34935739
Toxic shock syndrome	15.78	14.89	6	13994	402	34942529
Procedural pain	15.71	14.89	14	13986	4792	34938139
Shock haemorrhagic	15.69	14.89	21	13979	11333	34931598
Arthrofibrosis	15.60	14.89	4	13996	71	34942860
Staphylococcal bacteraemia	15.47	14.89	18	13982	8434	34934497
Prothrombin level decreased	15.45	14.89	8	13992	1120	34941811
Haemolytic anaemia	15.43	14.89	20	13980	10459	34932472
Pseudomembranous colitis	15.27	14.89	11	13989	2780	34940151
Laryngeal oedema	15.15	14.89	12	13988	3496	34939435
Reperfusion injury	15.05	14.89	4	13996	82	34942849
Acinetobacter infection	14.94	14.89	8	13992	1199	34941732
Delayed recovery from anaesthesia	14.90	14.89	7	13993	794	34942137

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	945.96	13.04	384	27324	35612	79681068
Anaphylactic reaction	499.69	13.04	329	27379	83414	79633266
Hypotension	246.10	13.04	499	27209	439818	79276862
Acute generalised exanthematous pustulosis	236.85	13.04	117	27591	17137	79699543
Hypoprothrombinaemia	208.42	13.04	49	27659	693	79715987
Kounis syndrome	148.71	13.04	56	27652	4226	79712454
Bronchospasm	136.78	13.04	93	27615	24766	79691914
Fatigue	124.25	13.04	86	27622	929641	78787039
Urticaria	118.96	13.04	223	27485	184978	79531702
Fear	117.99	13.04	81	27627	21905	79694775
Erythema	114.82	13.04	245	27463	223045	79493635
Vitamin K deficiency	108.78	13.04	29	27679	699	79715981
Arthrodesis	107.88	13.04	38	27670	2369	79714311
Renal injury	104.40	13.04	68	27640	16859	79699821
Anhedonia	99.68	13.04	63	27645	14835	79701845
Drug reaction with eosinophilia and systemic symptoms	94.36	13.04	114	27594	64130	79652550
Lymphoid tissue hypoplasia	92.83	13.04	27	27681	903	79715777
Type I hypersensitivity	92.15	13.04	40	27668	4358	79712322
Thymus hypoplasia	91.62	13.04	27	27681	946	79715734
Disseminated aspergillosis	87.92	13.04	27	27681	1091	79715589
Drug-induced liver injury	85.39	13.04	110	27598	66007	79650673
Unevaluable event	82.23	13.04	99	27609	55486	79661194
Clostridium difficile colitis	80.70	13.04	76	27632	32207	79684473
Blood pressure decreased	79.62	13.04	132	27576	99334	79617346
Rash	77.03	13.04	400	27308	577958	79138722
Renal failure	76.40	13.04	196	27512	200772	79515908
Coagulopathy	73.70	13.04	76	27632	35930	79680750
Clostridium test positive	71.81	13.04	38	27670	6416	79710264
Cardiac arrest	69.75	13.04	172	27536	171924	79544756
Allergy test negative	67.90	13.04	17	27691	317	79716363
Tachycardia	67.17	13.04	173	27535	177595	79539085
Post procedural complication	65.19	13.04	59	27649	23770	79692910
Emotional distress	63.76	13.04	74	27634	39895	79676785
Injury	63.57	13.04	104	27604	77392	79639288
Headache	58.97	13.04	85	27623	653687	79062993
Anaesthetic complication	56.64	13.04	25	27683	2834	79713846
Toxic epidermal necrolysis	54.17	13.04	72	27636	44509	79672171
Joint swelling	51.50	13.04	18	27690	288628	79428052
Drug hypersensitivity	50.75	13.04	222	27486	298694	79417986
Dizziness	49.89	13.04	66	27642	526375	79190305
Multiple organ dysfunction syndrome	49.56	13.04	121	27587	120125	79596555
Vitamin K decreased	49.40	13.04	10	27698	66	79716614
Shock	49.37	13.04	68	27640	43480	79673200
Eosinophilia	48.71	13.04	69	27639	45276	79671404
Hepatic function abnormal	48.07	13.04	89	27619	73018	79643662
Bradycardia	47.19	13.04	128	27580	135429	79581251
Hypovitaminosis	47.11	13.04	17	27691	1137	79715543
Product dose omission issue	46.69	13.04	14	27694	247523	79469157
Weight increased	46.64	13.04	19	27689	277367	79439313
Malaise	45.81	13.04	62	27646	489807	79226873
Cytomegalovirus viraemia	45.80	13.04	37	27671	12784	79703896
Disseminated intravascular coagulation	45.27	13.04	59	27649	35783	79680897
Toxicity to various agents	45.10	13.04	48	27660	421492	79295188
Brain herniation	43.63	13.04	29	27679	7434	79709246
Weight decreased	43.20	13.04	36	27672	355162	79361518
Angioedema	43.17	13.04	87	27621	75948	79640732
Rash maculo-papular	42.96	13.04	73	27635	56005	79660675
Death	42.40	13.04	83	27625	566431	79150249
Linear IgA disease	42.25	13.04	21	27687	3111	79713569
Post procedural hypotension	42.09	13.04	9	27699	80	79716600
Alopecia	42.00	13.04	14	27694	231341	79485339
Pseudomembranous colitis	41.74	13.04	25	27683	5349	79711331
Drug intolerance	41.39	13.04	20	27688	264099	79452581
Post procedural haematoma	40.92	13.04	19	27689	2423	79714257
Tubulointerstitial nephritis	40.80	13.04	58	27650	38177	79678503
Sinusitis	40.80	13.04	9	27699	195492	79521188
Hyperthermia malignant	40.67	13.04	20	27688	2897	79713783
Peripheral swelling	39.90	13.04	22	27686	269595	79447085
Renal impairment	39.80	13.04	133	27575	157650	79559030
Vascular purpura	39.53	13.04	20	27688	3078	79713602
Arthralgia	38.43	13.04	89	27619	571714	79144966
Face oedema	38.18	13.04	48	27660	28088	79688592
Device related infection	36.56	13.04	52	27656	34242	79682438
Diarrhoea	36.38	13.04	170	27538	880319	78836361
Haemolytic anaemia	35.35	13.04	37	27671	17783	79698897
Staphylococcal bacteraemia	34.89	13.04	31	27677	12187	79704493
Maternal exposure during delivery	34.06	13.04	14	27694	1332	79715348
Pseudomonal sepsis	33.72	13.04	23	27685	6151	79710529
Premature delivery	33.39	13.04	41	27667	23426	79693254
Asthenia	33.28	13.04	81	27627	511608	79205072
Ventricular tachycardia	32.66	13.04	55	27653	41880	79674800
Pain in extremity	32.20	13.04	48	27660	364490	79352190
Eyelid oedema	31.88	13.04	31	27677	13656	79703024
Toxic skin eruption	31.80	13.04	39	27669	22254	79694426
Post procedural haemorrhage	31.77	13.04	31	27677	13713	79702967
Nasopharyngitis	31.76	13.04	25	27683	253856	79462824
Procedural hypotension	31.62	13.04	15	27693	2008	79714672
Injection site pain	31.45	13.04	4	27704	129834	79586846
Cholestasis	31.23	13.04	61	27647	52048	79664632
Haemodynamic instability	30.81	13.04	34	27674	17348	79699332
Recurrence of neuromuscular blockade	30.68	13.04	9	27699	310	79716370
Shock haemorrhagic	30.09	13.04	36	27672	20024	79696656
Shoulder arthroplasty	30.08	13.04	17	27691	3265	79713415
Intentional product use issue	29.79	13.04	8	27700	152104	79564576
Pulseless electrical activity	29.17	13.04	30	27678	14130	79702550
Arthrofibrosis	29.02	13.04	7	27701	111	79716569
Heparin-induced thrombocytopenia	28.52	13.04	25	27683	9657	79707023
Strongyloidiasis	27.37	13.04	17	27691	3881	79712799
Infusion related reaction	27.16	13.04	24	27684	230213	79486467
Pathogen resistance	27.07	13.04	29	27679	14313	79702367
Drug eruption	27.02	13.04	52	27656	43883	79672797
Limb operation	26.77	13.04	16	27692	3410	79713270
Systemic lupus erythematosus	26.47	13.04	5	27703	121144	79595536
Septic shock	26.21	13.04	98	27610	122703	79593977
Purpura senile	26.19	13.04	9	27699	521	79716159
Tarsal tunnel syndrome	26.09	13.04	9	27699	527	79716153
Pyrexia	25.88	13.04	354	27354	678355	79038325
Conjunctival ulcer	25.84	13.04	6	27702	80	79716600
Pericarditis fungal	25.79	13.04	7	27701	181	79716499
Acute hepatic failure	25.47	13.04	41	27667	30072	79686608
Gastritis fungal	25.43	13.04	7	27701	191	79716489
Dysbiosis	25.25	13.04	11	27697	1208	79715472
Insomnia	25.00	13.04	29	27679	245141	79471539
Metabolic acidosis	24.87	13.04	74	27634	82455	79634225
Gastrointestinal disorder	24.74	13.04	6	27702	122199	79594481
Hepatic enzyme abnormal	24.69	13.04	21	27687	7789	79708891
Rash morbilliform	24.66	13.04	19	27689	6131	79710549
Tryptase increased	24.35	13.04	9	27699	644	79716036
Tonic clonic movements	24.25	13.04	13	27695	2251	79714429
Laryngeal oedema	23.96	13.04	21	27687	8108	79708572
Respiratory failure	23.86	13.04	125	27583	180786	79535894
Adrenal suppression	23.80	13.04	11	27697	1388	79715292
Contusion	23.70	13.04	11	27697	148765	79567915
Pruritus	23.69	13.04	225	27483	394423	79322257
Off label use	23.56	13.04	202	27506	907013	78809667
Muscle spasms	23.41	13.04	16	27692	174714	79541966
Cellulitis	23.25	13.04	87	27621	108973	79607707
Necrotising oesophagitis	22.92	13.04	10	27698	1103	79715577
Intentional product misuse	22.88	13.04	3	27705	95162	79621518
Mobility decreased	22.86	13.04	7	27701	122168	79594512
Arterial angioplasty	22.85	13.04	5	27703	50	79716630
Musculoskeletal pain	22.84	13.04	4	27704	102350	79614330
Embolic stroke	22.63	13.04	20	27688	7806	79708874
Brain oedema	22.20	13.04	35	27673	25228	79691452
Intrapericardial thrombosis	22.18	13.04	5	27703	58	79716622
Clostridium difficile infection	22.06	13.04	47	27661	42638	79674042
Acinetobacter infection	21.78	13.04	13	27695	2764	79713916
Airway peak pressure increased	21.57	13.04	7	27701	339	79716341
Lower respiratory tract infection	21.46	13.04	9	27699	129211	79587469
Pyomyositis	21.07	13.04	8	27700	617	79716063
Oropharyngeal pain	20.94	13.04	6	27702	109347	79607333
Catheter site haemorrhage	20.94	13.04	16	27692	5101	79711579
Musculoskeletal stiffness	20.93	13.04	18	27690	174990	79541690
Meningitis fungal	20.88	13.04	6	27702	192	79716488
Fall	20.75	13.04	93	27615	487536	79229144
Manipulation	20.75	13.04	5	27703	79	79716601
Therapeutic product effect decreased	20.66	13.04	16	27692	163847	79552833
Thrombotic microangiopathy	20.64	13.04	30	27678	20139	79696541
Post embolisation syndrome	20.46	13.04	5	27703	84	79716596
Skin graft	20.41	13.04	9	27699	1018	79715662
Contraindicated product administered	20.35	13.04	15	27693	157523	79559157
Circulatory collapse	20.07	13.04	42	27666	37626	79679054
Asthma	20.00	13.04	11	27697	135084	79581596
Macular oedema	19.98	13.04	16	27692	5458	79711222
Procedural haemorrhage	19.88	13.04	15	27693	4691	79711989
Myoclonus	19.86	13.04	35	27673	27625	79689055
Kidney transplant rejection	19.84	13.04	21	27687	10225	79706455
Aspartate aminotransferase increased	19.82	13.04	98	27610	138543	79578137
Electrocardiogram ST segment elevation	19.52	13.04	19	27689	8378	79708302
Hepatitis cholestatic	19.38	13.04	24	27684	13828	79702852
Cholestatic liver injury	19.23	13.04	15	27693	4926	79711754
Bacterial infection	19.21	13.04	37	27671	31243	79685437
Coagulation factor X level decreased	19.19	13.04	5	27703	110	79716570
Blood creatine phosphokinase MB increased	19.08	13.04	12	27696	2799	79713881
Delayed recovery from anaesthesia	19.03	13.04	10	27698	1663	79715017
Postoperative wound infection	19.02	13.04	23	27685	12938	79703742
Endotracheal intubation complication	18.95	13.04	8	27700	814	79715866
Generalised tonic-clonic seizure	18.95	13.04	45	27663	43865	79672815
Treatment failure	18.66	13.04	19	27689	170467	79546213
Lymphopenia	18.59	13.04	36	27672	30521	79686159
Disease progression	18.58	13.04	22	27686	184340	79532340
Hypoxia	18.49	13.04	78	27630	103165	79613515
Diabetes insipidus	18.46	13.04	15	27693	5222	79711458
Herpes simplex hepatitis	18.46	13.04	7	27701	538	79716142
Migraine	18.30	13.04	4	27704	87489	79629191
Memory impairment	18.20	13.04	8	27700	111726	79604954
Jaundice cholestatic	18.17	13.04	21	27687	11263	79705417
Encephalopathy	18.04	13.04	58	27650	67339	79649341
Hypoventilation	18.03	13.04	17	27691	7207	79709473
Arthropathy	17.99	13.04	21	27687	177090	79539590
Spinal cord haematoma	17.95	13.04	6	27702	319	79716361
COVID-19	17.92	13.04	17	27691	157657	79559023
Eye abscess	17.65	13.04	6	27702	336	79716344
Mixed liver injury	17.34	13.04	17	27691	7561	79709119
Resorption bone increased	17.31	13.04	9	27699	1466	79715214
Loss of personal independence in daily activities	17.26	13.04	7	27701	102573	79614107
Implant site haematoma	17.22	13.04	5	27703	166	79716514
Fear of death	17.07	13.04	9	27699	1507	79715173
Factor V inhibition	17.02	13.04	6	27702	375	79716305
Inappropriate schedule of product administration	16.90	13.04	13	27695	133615	79583065
Delayed graft function	16.67	13.04	12	27696	3495	79713185
Acute kidney injury	16.64	13.04	263	27445	519141	79197539
Procedural complication	16.60	13.04	17	27691	7966	79708714
Therapeutic product effect incomplete	16.42	13.04	15	27693	141630	79575050
Staphylococcal infection	16.37	13.04	51	27657	58244	79658436
Mycobacterial peritonitis	16.27	13.04	4	27704	69	79716611
Balance disorder	16.23	13.04	7	27701	98850	79617830
Discomfort	16.17	13.04	12	27696	125605	79591075
Cutaneous vasculitis	16.13	13.04	17	27691	8235	79708445
Feeling abnormal	16.04	13.04	19	27689	159180	79557500
Lip oedema	16.03	13.04	15	27693	6301	79710379
General physical health deterioration	16.01	13.04	46	27662	275192	79441488
Anaphylactoid reaction	15.97	13.04	14	27694	5408	79711272
Sleep disorder	15.86	13.04	5	27703	85672	79631008
Toxic shock syndrome	15.75	13.04	8	27700	1241	79715439
Coagulation factor VII level decreased	15.72	13.04	5	27703	227	79716453
Vestibular disorder	15.47	13.04	10	27698	2445	79714235
Alanine aminotransferase increased	15.40	13.04	103	27605	162467	79554213
Hypothermia	15.33	13.04	28	27680	22718	79693962
Dyspnoea	15.29	13.04	208	27500	856817	78859863
Jaundice	15.28	13.04	47	27661	53302	79663378
Psoriasis	15.26	13.04	6	27702	89581	79627099
Irregular breathing	15.22	13.04	6	27702	512	79716168
Swelling	15.11	13.04	33	27675	216678	79500002
Fungal infection	15.09	13.04	40	27668	41708	79674972
Wound	15.08	13.04	11	27697	116168	79600512
Cardiac valve vegetation	14.93	13.04	7	27701	912	79715768
Myalgia	14.91	13.04	26	27682	185615	79531065
Oxygen saturation decreased	14.88	13.04	86	27622	128961	79587719
Hypersensitivity vasculitis	14.83	13.04	15	27693	6928	79709752
Vertigo	14.77	13.04	3	27705	69079	79647601
Spontaneous haematoma	14.77	13.04	8	27700	1414	79715266
Influenza	14.69	13.04	14	27694	129592	79587088
Arthritis bacterial	14.66	13.04	17	27691	9149	79707531
Cataract subcapsular	14.63	13.04	7	27701	954	79715726
Torsade de pointes	14.60	13.04	25	27683	19287	79697393
Syncope	14.53	13.04	25	27683	179424	79537256
Laryngeal dyspnoea	14.44	13.04	5	27703	296	79716384
Cough	14.39	13.04	72	27636	366717	79349963
Drug chemical incompatibility	14.23	13.04	4	27704	118	79716562
Jaundice acholuric	14.20	13.04	4	27704	119	79716561
Exposure during pregnancy	14.10	13.04	71	27637	101061	79615619
Propionibacterium infection	14.04	13.04	5	27703	322	79716358
Blood creatinine increased	13.95	13.04	97	27611	154960	79561720
Systemic mastocytosis	13.89	13.04	5	27703	332	79716348
Altered state of consciousness	13.87	13.04	40	27668	43782	79672898
Decorticate posture	13.82	13.04	5	27703	337	79716343
Procedural pain	13.80	13.04	27	27681	23057	79693623
Cerebral infarction	13.80	13.04	41	27667	45635	79671045
Eosinophilic pneumonia acute	13.75	13.04	7	27701	1091	79715589
Injection site erythema	13.72	13.04	5	27703	78192	79638488
Respiratory distress	13.66	13.04	48	27660	58291	79658389
International normalised ratio increased	13.64	13.04	62	27646	84659	79632021
Stevens-Johnson syndrome	13.63	13.04	37	27671	39129	79677551
Hypoaesthesia	13.61	13.04	26	27682	179326	79537354
Endotracheal intubation	13.58	13.04	12	27696	4685	79711995
Back pain	13.54	13.04	57	27651	304123	79412557
Hypokalaemia	13.49	13.04	91	27617	143949	79572731
Status epilepticus	13.43	13.04	28	27680	25013	79691667
Fibromyalgia	13.34	13.04	3	27705	64337	79652343
Gait disturbance	13.34	13.04	33	27675	207473	79509207
Blood pressure increased	13.28	13.04	34	27674	211326	79505354
Serotonin syndrome	13.21	13.04	40	27668	44987	79671693
Stupor	13.15	13.04	14	27694	6858	79709822
Eosinophilic myocarditis	13.04	13.04	7	27701	1215	79715465

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DB04	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:36047	antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bacterial septicemia	indication	10001005	DOID:0040085
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Staphylococcal pneumonia	indication	22754005
Pneumonia due to Streptococcus	indication	34020007
Lower respiratory tract infection	indication	50417007
Bacterial pneumonia	indication	53084003	DOID:874
Cholangitis	indication	82403002	DOID:9446
Infection of bone	indication	111253001
Bacterial endocarditis	indication	301183007
Bacterial urinary infection	indication	312124009
Infectious disorder of joint	indication	363162000
Infection of biliary tract	indication	846685008
Prevention of Perioperative Infection	indication
Genitourinary Tract Infections	indication
Prevention of Bacterial Endocarditis	off-label use
Acute nephropathy	contraindication	58574008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Factor II deficiency	contraindication	73975000
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.22	acidic
pKa2	12.21	acidic
pKa3	1.52	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 1GM BASE/VIAL	CEFAZOLIN AND DEXTROSE	B BRAUN	N050779	July 27, 2000	RX	INJECTABLE	INJECTION	Nov. 23, 2023	NEW PATIENT POPULATION
EQ 2GM BASE/VIAL	CEFAZOLIN AND DEXTROSE	B BRAUN	N050779	Jan. 13, 2012	RX	INJECTABLE	INJECTION	Nov. 23, 2023	NEW PATIENT POPULATION
EQ 500MG BASE/VIAL	CEFAZOLIN AND DEXTROSE	B BRAUN	N050779	July 27, 2000	DISCN	INJECTABLE	INJECTION	Nov. 23, 2023	NEW PATIENT POPULATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR				CHEMBL	CHEMBL
Penicillin-binding protein 1A	Enzyme		PBPA_CLOPE					WOMBAT-PK

External reference:

ID	Source
4019659	VUID
N0000147751	NUI
D00905	KEGG_DRUG
27164-46-1	SECONDARY_CAS_RN
203171	RXNORM
C0007546	UMLSCUI
CHEBI:474053	CHEBI
CHEMBL1435	ChEMBL_ID
CHEMBL1200523	ChEMBL_ID
D002437	MESH_DESCRIPTOR_UI
DB01327	DRUGBANK_ID
10935	IUPHAR_LIGAND_ID
2991	INN_ID
IHS69L0Y4T	UNII
33255	PUBCHEM_CID
35509	MMSL
4371	MMSL
948	MMSL
d00007	MMSL
387470007	SNOMEDCT_US
80972005	SNOMEDCT_US
81088002	SNOMEDCT_US
4017460	VANDF
4019659	VANDF
002720	NDDF
004841	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9139	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAVENOUS	NDA	28 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9140	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	28 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9261	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	23 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9262	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9262	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9665	INJECTION, POWDER, FOR SOLUTION	20 g	INTRAVENOUS	ANDA	23 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9923	INJECTION, POWDER, FOR SOLUTION	225 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9923	INJECTION, POWDER, FOR SOLUTION	225 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9924	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9924	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9983	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	23 sections
Cefazolin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3103	SOLUTION	1 g	INTRAVENOUS	NDA	27 sections
Cefazolin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3105	SOLUTION	2 g	INTRAVENOUS	NDA	27 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3503	INJECTION, SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3503	INJECTION, SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3503	INJECTION, SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3508	INJECTION, SOLUTION	2 g	INTRAVENOUS	NDA	26 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3508	INJECTION, SOLUTION	2 g	INTRAVENOUS	NDA	26 sections
CEFAZOLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9833	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	17 sections
CEFAZOLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9833	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	17 sections
CEFAZOLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9833	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	17 sections
CEFAZOLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9834	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	10 sections
CEFAZOLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9834	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	10 sections
CEFAZOLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9834	INJECTION, POWDER, FOR SOLUTION	330 mg	INTRAMUSCULAR	ANDA	10 sections
CEFAZOLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9835	INJECTION, POWDER, FOR SOLUTION	225 mg	INTRAMUSCULAR	ANDA	11 sections
CEFAZOLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9835	INJECTION, POWDER, FOR SOLUTION	225 mg	INTRAMUSCULAR	ANDA	11 sections
CEFAZOLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9835	INJECTION, POWDER, FOR SOLUTION	225 mg	INTRAMUSCULAR	ANDA	11 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2585	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	23 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3450	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	21 sections
Cefazolin	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3451	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	21 sections